Eric I Richman - Net Worth and Insider Trading
Eric I Richman Net Worth
The estimated net worth of Eric I Richman is at least $963,375 dollars as of 2024-04-19. Eric I Richman is the CHIEF EXECUTIVE OFFICER of Gain Therapeutics Inc and owns about 232,558 shares of Gain Therapeutics Inc (GANX) stock worth over $708,651. Eric I Richman is the Director of ADMA Biologics Inc and owns about 36,530 shares of ADMA Biologics Inc (ADMA) stock worth over $224,842. Eric I Richman is also the Director of NeuBase Therapeutics Inc and owns about 72,707 shares of NeuBase Therapeutics Inc (NBSE) stock worth over $29,883. Details can be seen in Eric I Richman's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Eric I Richman has not made any transactions after 2022-05-25 and currently still holds the listed stock(s).
Transaction Summary of Eric I Richman
Eric I Richman Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Eric I Richman owns 4 companies in total, including NeuBase Therapeutics Inc (NBSE) , ADMA Biologics Inc (ADMA) , and Altimmune Inc (ALT) among others .
Click here to see the complete history of Eric I Richman’s form 4 insider trades.
Insider Ownership Summary of Eric I Richman
Ticker | Comapny | Transaction Date | Type of Owner |
---|---|---|---|
NBSE | NeuBase Therapeutics Inc | 2022-03-04 | director |
ADMA | ADMA Biologics Inc | 2018-06-08 | director |
ALT | Altimmune Inc | 2009-01-21 | SVP & Business Development |
GANX | Gain Therapeutics Inc | 2022-05-25 | director |
Eric I Richman Latest Holdings Summary
Eric I Richman currently owns a total of 3 stocks. Among these stocks, Eric I Richman owns 232,558 shares of Gain Therapeutics Inc (GANX) as of May 25, 2022, with a value of $708,651 and a weighting of 73.56%. Eric I Richman owns 36,530 shares of ADMA Biologics Inc (ADMA) as of June 8, 2018, with a value of $224,842 and a weighting of 23.34%. Eric I Richman also owns 72,707 shares of NeuBase Therapeutics Inc (NBSE) as of March 4, 2022, with a value of $29,883 and a weighting of 3.1%.
Latest Holdings of Eric I Richman
Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
---|---|---|---|---|---|
GANX | Gain Therapeutics Inc | 2022-05-25 | 232,558 | 3.05 | 708,651 |
ADMA | ADMA Biologics Inc | 2018-06-08 | 36,530 | 6.16 | 224,842 |
NBSE | NeuBase Therapeutics Inc | 2022-03-04 | 72,707 | 0.41 | 29,883 |
Holding Weightings of Eric I Richman
Eric I Richman Form 4 Trading Tracker
According to the SEC Form 4 filings, Eric I Richman has made a total of 3 transactions in Gain Therapeutics Inc (GANX) over the past 5 years, including 3 buys and 0 sells. The most-recent trade in Gain Therapeutics Inc is the acquisition of 2,482 shares on May 25, 2022, which cost Eric I Richman around $6,404.
According to the SEC Form 4 filings, Eric I Richman has made a total of 0 transactions in ADMA Biologics Inc (ADMA) over the past 5 years. The most-recent trade in ADMA Biologics Inc is the acquisition of 5,230 shares on June 8, 2018, which cost Eric I Richman around $24,999.
According to the SEC Form 4 filings, Eric I Richman has made a total of 2 transactions in NeuBase Therapeutics Inc (NBSE) over the past 5 years, including 2 buys and 0 sells. The most-recent trade in NeuBase Therapeutics Inc is the acquisition of 3,880 shares on March 4, 2022, which cost Eric I Richman around $6,363.
Insider Trading History of Eric I Richman
- 1
Eric I Richman Trading Performance
GuruFocus tracks the stock performance after each of Eric I Richman's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Eric I Richman is 18.85%. GuruFocus also compares Eric I Richman's trading performance to market benchmark return within the same time period. The performance of stocks bought by Eric I Richman within 3 months outperforms 6 times out of 8 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Eric I Richman's insider trading performs compared to the benchmark.
Performance of Eric I Richman
Average Return
7.64%
Outperforming Transactions
38%
1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
---|---|---|---|---|---|---|
Return(%) | 14.34 | 18.85 | 6.71 | 7.64 | -30.76 | -31.79 |
Relative Return to S&P 500(%) | 13.5 | 14.85 | 5.9 | 0.83 | -39.43 | -44.12 |
Eric I Richman Ownership Network
Ownership Network List of Eric I Richman
Ownership Network Relation of Eric I Richman
Eric I Richman Owned Company Details
What does NeuBase Therapeutics Inc do?
Who are the key executives at NeuBase Therapeutics Inc?
Eric I Richman is the director of NeuBase Therapeutics Inc. Other key executives at NeuBase Therapeutics Inc include 10 percent owner Symetryx Corp , 10 percent owner Barry Shiff , and 10 percent owner Aleta Shiff .
NeuBase Therapeutics Inc (NBSE) Insider Trades Summary
Over the past 18 months, Eric I Richman made no insider transaction in NeuBase Therapeutics Inc (NBSE). Other recent insider transactions involving NeuBase Therapeutics Inc (NBSE) include a net sale of 428,444 shares made by Symetryx Corp ,
In summary, during the past 3 months, insiders sold 0 shares of NeuBase Therapeutics Inc (NBSE) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 489,520 shares of NeuBase Therapeutics Inc (NBSE) were sold and 61,076 shares were bought by its insiders, resulting in a net sale of 428,444 shares.
NeuBase Therapeutics Inc (NBSE)'s detailed insider trading history can be found in Insider Trading Tracker table.
NeuBase Therapeutics Inc Insider Transactions
Eric I Richman Mailing Address
Above is the net worth, insider trading, and ownership report for Eric I Richman. You might contact Eric I Richman via mailing address: C/o Rev Capital Ii, Llc, 9740 Sorrel Ave, Potomac Md 20854.